TB-500 Guide
Thymosin Beta-4: The Systemic Healing Peptide
TB-500 is the synthetic form of Thymosin Beta-4 (Tβ4), a protein naturally found in virtually every human cell. Unlike BPC-157 which heals locally, TB-500 acts systemically — injected anywhere, it promotes healing everywhere through actin dynamics and cell migration. It is one of the most researched peptides for full-body recovery, cardiac protection, and anti-fibrotic effects.
What Is TB-500?
TB-500 refers to the synthetic peptide version of Thymosin Beta-4 (Tβ4), a naturally occurring protein present in the cytoplasm of virtually every nucleated human cell. Tβ4 is a 43 amino acid protein, but when researchers and vendors refer to "TB-500," they typically mean a biologically active fragment — commonly identified as the 17 amino acid sequence (Ac-LKKTETQ or similar) that retains the core actin-binding properties of the full Tβ4 molecule.
The defining feature of Thymosin Beta-4 — and the property that makes TB-500 so distinctive — is its systemic action. Most healing peptides require proximity to the injury site for maximum effect. TB-500, when injected subcutaneously at any location, distributes systemically and promotes repair throughout the body simultaneously. This is because its mechanism operates at the cellular level across all tissue types.
Tβ4 is not orally bioavailable — peptide bonds are broken down in the GI tract before systemic absorption can occur at meaningful concentrations. Subcutaneous injection is the only established route. The peptide cannot be taken as a capsule or dissolved in a beverage for systemic effect.
Full Thymosin Beta-4 protein; TB-500 commercially represents the active healing fragment with the key actin-sequestering domain.
Injected anywhere, heals everywhere — TB-500's systemic distribution is what distinguishes it from localized healing peptides.
Tβ4 levels naturally rise after cardiac injury — exogenous TB-500 mimics and amplifies this endogenous repair response.
How TB-500 Works: Mechanisms
Actin Sequestration & Cell Migration
Thymosin Beta-4's primary and best-characterized mechanism is G-actin sequestration. Actin exists in two forms: globular (G-actin, monomeric) and filamentous (F-actin, polymerized). Tβ4 binds G-actin and prevents its premature polymerization, maintaining a pool of free actin available for rapid cell migration. This is critical for wound healing — cells cannot migrate to repair tissue without actin dynamics. TB-500 effectively accelerates the supply of building blocks for cellular movement.
Muscle Satellite Cell Activation
In skeletal muscle, TB-500 activates satellite cells — the resident stem cells responsible for muscle repair and regeneration. After injury, muscle satellite cells proliferate and differentiate into new muscle fibers. Tβ4 upregulates the expression of key myogenic transcription factors (MyoD, Myf5) that drive this differentiation process. This makes TB-500 particularly relevant for muscle tears, contusions, and surgery-related muscle damage.
Cardiac Progenitor Cell Activation
One of TB-500's most clinically significant properties is its role in cardiac repair. Tβ4 is naturally elevated in cardiac tissue following ischemic injury — the heart upregulates it as part of its self-repair attempt. Exogenous TB-500 amplifies this response: it activates Isl1+ cardiac progenitor cells in the epicardium, promotes their migration into damaged myocardium, and can stimulate cardiomyocyte differentiation. It also reduces cardiac fibrosis — the scar tissue that progressively impairs cardiac function after heart attacks.
Anti-Fibrotic & Anti-Inflammatory
TB-500 actively reduces fibrosis — excess scar tissue formation — across multiple organ systems including cardiac, hepatic, and pulmonary tissue. Fibrosis is a major driver of organ failure in chronic disease. Tβ4 reduces TGF-β1 signaling (the primary driver of fibrosis) and downregulates pro-inflammatory cytokines including TNF-α and IL-1β. This anti-inflammatory and anti-fibrotic combination makes TB-500 relevant not just for acute injury but for chronic inflammatory conditions.
TB-500 Dosage & Protocol
TB-500 protocols typically follow a two-phase structure: a loading phase with higher, more frequent dosing to rapidly establish tissue levels, followed by a maintenance phase with reduced frequency to sustain effect. Because TB-500 acts systemically, injection site proximity to the injury does not matter — abdominal subcutaneous injection is standard.
Loading Phase (Weeks 1–6)
- • Dose: 2–2.5mg per injection
- • Frequency: Twice weekly (e.g., Monday + Thursday)
- • Weekly total: 5mg
- • Route: Subcutaneous injection
- • Site: Abdomen or any convenient SQ site
- • Goal: Rapidly raise systemic Tβ4 levels to therapeutic concentrations
Maintenance Phase (Weeks 7+)
- • Dose: 2–5mg per injection
- • Frequency: Once every 1–2 weeks
- • Weekly total: 2.5–5mg
- • Route: Subcutaneous injection
- • Goal: Sustain healing response during recovery plateau
- • Duration: As needed — cycle off after 12–16 weeks total
TB-500 Effects by System
Musculoskeletal Recovery
- Muscle tears: Activates satellite cells for rapid myofiber regeneration; reduces inflammation at injury site through cytokine modulation.
- Tendon and ligament: Promotes collagen synthesis and matrix remodeling via cell migration — complementary to BPC-157's VEGF-driven angiogenesis approach.
- Bone healing: Some evidence for periosteum activation and mesenchymal stem cell recruitment to fracture sites.
- Post-surgery recovery: Widely used to accelerate return to function after orthopedic and soft tissue surgical procedures.
Cardiovascular
- Post-MI healing: Promotes cardiac progenitor cell activation and migration into infarcted zones — potential for cardiomyocyte regeneration that was once considered impossible.
- Anti-fibrotic: Reduces the scar tissue accumulation that drives progressive heart failure after myocardial infarction.
- Angiogenesis: Promotes new blood vessel formation in ischemic cardiac tissue — improving oxygen delivery to at-risk myocardium.
- Endothelial protection: Protective effects on coronary endothelium via anti-inflammatory and eNOS-modulating mechanisms.
Hair Follicle Activation
- Anagen phase prolongation: TB-500 stimulates hair follicle stem cells and prolongs the active growth (anagen) phase of the hair cycle.
- Follicle enlargement: Increases follicle size, which correlates with thicker, stronger hair shafts — relevant to androgenetic alopecia.
- Scalp delivery: Some protocols use subcutaneous scalp injection for local effect; systemic injection also reaches follicles via blood supply.
Anti-Fibrotic Applications
- Reduced scar tissue: TGF-β1 suppression reduces excessive fibrotic response — relevant after surgery, burns, and chronic inflammatory conditions.
- Hepatic fibrosis: Preclinical data suggests Tβ4 may reduce liver fibrosis progression in NAFLD/NASH models.
- Pulmonary: Anti-fibrotic research relevant to conditions like idiopathic pulmonary fibrosis — very early stage.
The BPC-157 + TB-500 Stack
The BPC-157 + TB-500 stack is the most popular and best-regarded combination in the peptide research community — and for good mechanistic reason. The two compounds approach tissue repair through genuinely non-overlapping pathways:
BPC-157 Contributes
- • Angiogenesis (VEGF-driven) — new blood vessels to the injury
- • GH receptor upregulation in fibroblasts
- • FAK/paxillin signaling activation
- • NO system balance and anti-inflammation
- • Localized or oral gut healing
TB-500 Contributes
- • Actin dynamics and cell migration machinery
- • Muscle satellite cell activation
- • Anti-fibrotic TGF-β1 suppression
- • Cardiac progenitor cell recruitment
- • Systemic distribution from any injection site
Together, BPC-157 creates the vascular and growth factor environment for healing while TB-500 provides the cellular migration machinery that physically repairs tissue. No known interactions or contraindications between the two compounds have been reported. They are typically kept in separate vials and injected sequentially.
Frequently Asked Questions
What is TB-500 and how does it differ from BPC-157?
TB-500 is the synthetic form of Thymosin Beta-4 (Tβ4), a 43 amino acid protein naturally present in all human cells. Unlike BPC-157 which is derived from human gastric juice and acts through growth factor and angiogenesis pathways, TB-500 works primarily by sequestering G-actin to enable cell migration — its healing action is systemic (injected anywhere, heals anywhere) rather than localized. TB-500 is not orally bioavailable and must be administered by subcutaneous injection.
What is the standard TB-500 dosage protocol?
The most commonly reported protocol is a 6-week loading phase at 5mg per week (typically 2.5mg twice weekly), followed by a maintenance phase of 5mg every 1–2 weeks. Some practitioners use 2–2.5mg twice weekly throughout the cycle. TB-500 is administered subcutaneously and can be injected at any site — its systemic action means proximity to the injury is not required for efficacy.
Can TB-500 help with heart health?
Thymosin Beta-4 levels naturally rise after cardiac injury as part of the body's self-repair attempt. Research has shown that exogenous Tβ4 (TB-500) promotes cardiac progenitor cell activation, supports cardiomyocyte differentiation, and reduces cardiac fibrosis — a key driver of heart failure progression. While large human RCTs are lacking, the mechanistic and preclinical data is compelling. TB-500 is one of the few peptides with documented cardiac progenitor cell activation potential.
Track Your TB-500 Protocol with Shotlee
Log every injection, monitor your recovery timeline, and build a personal dataset that tells you exactly how TB-500 is working for your body.
Start Tracking Free